ENLV logo

ENLV
Enlivex Therapeutics Ltd

7,949
Mkt Cap
$167M
Volume
80,304.00
52W High
$2.10
52W Low
$0.66
PE Ratio
0.03
ENLV Fundamentals
Price
$0.736
Prev Close
$0.7202
Open
$0.737
50D MA
$0.8943
Beta
0.72
Avg. Volume
548,214.74
EPS (Annual)
$25.48
P/B
0.09
Rev/Employee
$0.00
$28.88
Loading...
Loading...
News
all
press releases
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
News Placeholder
More News
News Placeholder
HC Wainwright Issues Pessimistic Outlook for ENLV Earnings
Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Enlivex Therapeutics in a research note issued to...
News Placeholder
Research Analysts Set Expectations for ENLV Q1 Earnings
Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.02) per share...
News Placeholder
HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock
HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday...
News Placeholder
Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut shares of Enlivex Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
News Placeholder
Enlivex Therapeutics Q4 Earnings Call Highlights
Enlivex Therapeutics (NASDAQ:ENLV) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what they described as a dual-engine strategy that combines clinical-stage...
News Placeholder
Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS
Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $12.85 earnings per share for the quarter, beating analysts' consensus...
News Placeholder
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
News Placeholder
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday
Enlivex Therapeutics (NASDAQ:ENLV) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-enlivex-therapeutics-ltd-stock...
News Placeholder
Enlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available